Manipulation of p53 Protein in Bladder Cancer Treatment

Mansor, Siti Farizan

doi:10.31436/imjm.v20i1.1764

Cited by 2 publications

(3 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Reducing MDM4 expression restores the p53 function and increases apoptotic cells [25]. The apoptotic effects of compound 13e were determined in U87 cells by flow cytometry.…”

Section: Mechanistic Analyses Of 13e Against U87 Cellsmentioning

confidence: 99%

“…The mechanism by which 13e induces apoptosis in U87 cells may be related to its ability to downregulate MDM4 expression and stabilize p53 protein. Reducing MDM4 expression restores the p53 function and increases apoptotic cells [25]. The apoptotic effects of compound 13e were determined in U87 cells by flow cytometry.…”

Section: Mechanistic Analyses Of 13e Against U87 Cellsmentioning

confidence: 99%

See 1 more Smart Citation

Novel 9-Methylanthracene Derivatives as p53 Activators for the Treatment of Glioblastoma Multiforme

Feng,

Wang,

et al. 2024

Molecules

View full text Add to dashboard Cite

Glioblastoma multiforme, a highly aggressive and lethal brain tumor, is a substantial clinical challenge and a focus of increasing concern globally. Hematological toxicity and drug resistance of first-line drugs underscore the necessity for new anti-glioma drug development. Here, 43 anthracenyl skeleton compounds as p53 activator XI-011 analogs were designed, synthesized, and evaluated for their cytotoxic effects. Five compounds (13d, 13e, 14a, 14b, and 14n) exhibited good anti-glioma activity against U87 cells, with IC50 values lower than 2 μM. Notably, 13e showed the best anti-glioma activity, with an IC50 value up to 0.53 μM, providing a promising lead compound for new anti-glioma drug development. Mechanistic analyses showed that 13e suppressed the MDM4 protein expression, upregulated the p53 protein level, and induced cell cycle arrest at G2/M phase and apoptosis based on Western blot and flow cytometry assays.

show abstract

“…Reducing MDM4 expression restores the p53 function and increases apoptotic cells [25]. The apoptotic effects of compound 13e were determined in U87 cells by flow cytometry.…”

Section: Mechanistic Analyses Of 13e Against U87 Cellsmentioning

confidence: 99%

Section: Mechanistic Analyses Of 13e Against U87 Cellsmentioning

confidence: 99%

Novel 9-Methylanthracene Derivatives as p53 Activators for the Treatment of Glioblastoma Multiforme

Feng,

Wang,

et al. 2024

Molecules

View full text Add to dashboard Cite

show abstract

“…About 60% of bladder cancer cases result in mutp53 (mutant-p53) in exon 5-11. mutp53 is commonly associated with the mutRb gene in high-grade, invasive, and poorly prognostic bladder cancer [32]. Up to 20% of all BC cases were caused by the p53 gene mutation in exons 1-4, accompanied by mutCDKN2a and loss of ARF function.…”

Section: Bladder Cancermentioning

confidence: 99%

Role of p53 in Human Cancers

Coşkun¹,

Tutar²,

Al³

et al. 2022

P53 - A Guardian of the Genome and Beyond

View full text Add to dashboard Cite

TP53 codes tumor protein 53-p53 that controls the cell cycle through binding DNA directly and induces reversible cell-cycle arrest. The protein activates DNA repair genes if mutated DNA will be repaired or activates apoptotosis if the damaged DNA cannot be fixed. Therefore, p53, so-called the “guardian of the genome,” promote cell survival by allowing for DNA repair. However, the tumor-suppressor function of p53 is either lost or gained through mutations in half of the human cancers. In this work, functional perturbation of the p53 mechanism is elaborated at the breast, bladder, liver, brain, lung cancers, and osteosarcoma. Mutation of wild-type p53 not only diminishes tumor suppressor activity but transforms it into an oncogenic structure. Further, malfunction of the TP53 leads accumulation of additional oncogenic mutations in the cell genome. Thus, disruption of TP53 dependent survival pathways promotes cancer progression. This oncogenic TP53 promotes cell survival, prevents cell death through apoptosis, and contributes to the proliferation and metastasis of tumor cells. The purpose of this chapter is to discuss the contribution of mutant p53 to distinct cancer types.

show abstract

Manipulation of p53 Protein in Bladder Cancer Treatment

Cited by 2 publications

References 51 publications

Novel 9-Methylanthracene Derivatives as p53 Activators for the Treatment of Glioblastoma Multiforme

Novel 9-Methylanthracene Derivatives as p53 Activators for the Treatment of Glioblastoma Multiforme

Role of p53 in Human Cancers

Contact Info

Product

Resources

About